Skip to main content

Decitabine and cedazuridine

Details of the Drug
Generic Name:
Decitabine and cedazuridine
deh-SY-tuh-been and SEE-daz-YOOR-ih-deen
Drug Type:
Combination of decitabine, a nucleoside metabolic inhibitor, and cedazuridine, a cytidine deaminase inhibitor
How the Drug is Given:

Tablet, for oral use

Inqovi ®
Decitabine and cedazuridine

Indications and Usage

Inqovi is FDA approved for treatment of adult patients with myelodysplastic syndromes (MDS), including previously treated and untreated, de novo and secondary MDS with the following French American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia [CMML]) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups.


Side effects needing medical attention

Most common adverse reactions are fatigue, constipation, hemorrhage, muscle pain or muscle ache (myalgia), mucositis, joint pain (arthralgia), nausea, difficulty breathing (dyspnea), diarrhea, rash, dizziness, febrile neutropenia, swelling caused by excess fluid trapped in the body's tissues (edema), headache, cough, decreased appetite, upper respiratory tract infection, pneumonia, and transaminase increased.


For information on how to manage the costs of drug therapy, please see Financial Support, or to speak with an Information Specialist, call (800) 955-4572.